MedTrace Logo

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00006864 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-01-09

No results posted yet for this study

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells.

PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.

Conditions

Interventions

BIOLOGICAL

aldesleukin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Chiron Corporation

    collaborator INDUSTRY

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Cindy Connell, MD, PhD · University Hospitals Seidman Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-07-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006864 on ClinicalTrials.gov